Solace Biotech Product Start With Letter "O"

463 views
358 views

Published on

Published in: Education, Sports, Automotive
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
463
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Solace Biotech Product Start With Letter "O"

  1. 1. Solace Biotech Product s
  2. 2. Name of BraNds start With alphaBet “o”
  3. 3. Onlit Opidol SR- 100 Opidol – P Opidol Injection O
  4. 4. Onlit -MD contains Ondansetron Indications Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. Prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, ondansetron tablets and syrup is recommended even when the incidence of postoperative nausea and/or vomiting is low.
  5. 5. DOSAGE AND ADMINISTRATION 1. Prevention of Nausea and Vomiting Associated With Highly Emetogenic Cancer Chemotherapy o The recommended adult oral dosage of Onlit is 24 mg given as three 8-mg tablets administered 30 minutes before the start of single-day highly emetogenic chemotherapy, including cisplatin ≥ 50 mg/m 2 . Multiday, singledose administration of a 24 mg dosage has not been studied. o Intravenous ondansetron has been shown to be equally effective in the following dose schedules over the first 24 hours of chemotherapy: A single dose of 8mg( Onlit- Rapitab 8) by slow intravenous or intramuscular injection immediately before
  6. 6. A single dose of 32mg diluted in 50-100ml of saline or other compatible infusion fluid and infused over not less than 15 minutes immediately before chemotherapy. The selection of dose regimen should be determined by the severity of the emetogenic challenge. The efficacy of ondansetron in highly emetogenic chemotherapy may be enhanced by the addition of a single intravenous dose of dexamethasone sodium phosphate, 20mg administered prior to chemotherapy. 2. Prevention of Nausea and Vomiting Associated With Moderately Emetogenic Cancer Chemotherapy • The recommended adult oral dosage is one 8-mg Onlit Tablet given twice a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. One 8-mg Onlit Tablet should be administered twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy. Pediatric Use • For pediatric patients 12 years of age and older, the dosage is the same as for adults. For pediatric patients 4 through 11 years of age, the dosage is one 4-mg Onlit Tablet or 4 mg (2 teaspoonful equivalent to 10ml) of Onlit Syrup given 3 times a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with subsequent doses 4 and 8 hours after the first dose. One 4-mg Onlit Tablet or 4mg (2 teaspoonful equivalent to 2 mg of 10ml) of Onlit Syrup should be administered 3 times a day (every 8 hours) for 1 to 2 days after completion of chemotherapy.
  7. 7. 3. Prevention of Nausea and Vomiting Associated With Radiotherapy, Either Total Body Irradiation, or Single High-Dose Fraction or Daily Fractions to the Abdomen • The recommended oral dosage is one 8-mg Onlit Tablet given 3 times a day. • For total body irradiation , one 8-mg Onlit Tablet should be administered 1 to 2 hours before each fraction of radiotherapy administered each day. For single high-dose fraction radiotherapy to the abdomen , one 8-mg Onlit Tablet should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.For daily fractionated radiotherapy to the abdomen , one 8-mg Onlit Tablet should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day radiotherapy is given. 4.Postoperative Nausea and Vomiting PONV The recommended dosage is 16 mg given as two 8-mg OnlitTablets 1 hour before induction of anesthesia. For the prevention of PONV Ondansetron can be administered orally or by intravenous or intramuscular injection. Ondansetron may be administered as a single dose of 4mg given by intramuscular or slow intravenous injection at induction of anesthesia. For treatment of established PONV a single dose of 4mg given by intramuscular or slow intravenous injection is recommended.
  8. 8. Opidol- SR 100 contains Tramadol Hydrochloride 100 mg (Sustained Release) Opidol-SR Non- Opioid Analgesic Tramadol Sustained Released Tab. Composition: Each Tablet contains Tramadol 100mg (Sustained Released) Indications: Post operative pain, Trauma, Osteo arthiritis flair Opidol-SR tablets are designed to release the pain reliever gradually over several hours. Dosage and Administration Opidol- SR is not recommended for children under 12 years. one or two Opidol- SR 100 mg tablet(s) once or twice a day (morning and evening)
  9. 9. Opidol – P Contains Tablets Tramadol 50 mg Paracetamol 500 mg Indication Post operative pain, Trauma, Osteo arthiritis flair Dosage and Administration Acute pain: 2 tablets every 4 to 6 hours as needed for pain relief. Do not exceed 8 tablets per day. To be used in adults and children over 16 years of age. Do not exceed the recommended dose. Contra-Indications Opidol-P is contra-indicated in patients with a known hypersensitivity to tramadol, paracetamol or other opioids such as codeine. It is also contraindicated in cases of severe liver function impairment and in acute intoxication with alcohol It should not be administered to patients who are receiving monoamine oxidase inhibitors or within two weeks of their withdrawal. Opidol-P must not be used for narcotic withdrawal treatment
  10. 10. Opidol-P should not be given to patients with respiratory depression especially in the presence of cyanosis and excessive bronchial secretions. Opidol-P should not be given to patients with increased intracranial pressure or central nervous system depression due to head injury or cerebral disease. Safety during pregnancy and lactation has not been established. Tramadol has beenshown to cross the placenta.
  11. 11. Opidol –Injection Opidol Injection Composition : Each ampoule contains: Tramadol…. 50mg/1ml Indications: Severe acute and chronic pain in diagnostic procedures and surgical pain, arthralgia, pain associated with fractures and osteoarthritis. Dosage: Oral :50-100 mg 2-3 times daily. Maximum 400mg divided doses . IV/IM/SC 100 mg Child 1.15 mg/kg Maximum 500 mg.

×